|Bid||0.00 x 0|
|Ask||2,278.45 x 0|
|Day's Range||2,239.05 - 2,291.00|
|52 Week Range||1,887.00 - 2,615.00|
|PE Ratio (TTM)||27.49|
|Earnings Date||May 10, 2018 - May 14, 2018|
|Forward Dividend & Yield||20.00 (0.90%)|
|1y Target Est||2,587.45|
The Zacks Analyst Blog Highlights: Dr. Reddy'sLaboratories, Infosys, ICICI Bank and HDFC Bank
The Hyderabad, India-based company said it had net income of 40 cents per share. The pharmaceutical posted revenue of $543 million in the period. Doctor Reddy's shares have dropped 19 percent since the ...
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2018 under International Financial Reporting Standards .
Net profit came in at 4.76 billion rupees ($69.31 million) in the quarter ended June 30, compared with 666 million rupees a year earlier, the company said. Analysts on average had expected a net profit of 2.98 billion rupees, according to Thomson Reuters I/B/E/S. Dr.Reddy's got approval to sell versions of Indivior Plc's best-selling opioid addiction treatment last month, materially hurting the British drugmaker's revenue and forcing it to scrap its full-year forecast amid market share loss.
Indian generic drugmaker Dr.Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version ...
Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version ...
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Hervycta® , a biosimilar of Roche’s Herceptin®, in India, indicated for the treatment of HER2-positive cancers .
Indivior said on Wednesday the impact from the launch of a generic version of its opioid addiction treatment "could be materially higher" in 2018, as the British drugmaker posted a second straight drop in quarterly profit. The company, which issued a profit warning this month citing significant market share loss for star drug Suboxone Film, said adjusted net income fell 21.3 percent to $70 million in the quarter ended June 30 from a year earlier.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic version of Nexium® 24HR Capsules in the United States market as approved by the U.S.
Score one for Indivior Plc. Dr. Reddy's fell about 9% in trading Monday on the news of the preliminary injunction. The two competitors are currently embroiled in a patent-infringement lawsuit over Indivior's Suboxone sublingual film treatment since June, when Dr. Reddy's received FDA approval for its generic version.
Dr. Reddy’s Laboratories Ltd. today announced its intent to appeal the decision made by the U.S.
A U.S. court has granted Indivior a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior said on Friday. Indivior, a maker of opioid addiction treatments spun-off from Reckitt Benckiser in 2014, has been involved in a number of legal battles with generic drugmakers over their versions of its Suboxone Film . Indivior got a temporary restraining order against Dr.Reddy's in June, but the British firm saw the impact from a generic in the market as Suboxone's market share dropped rapidly by 2.5 percent to 52 percent.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® Tablets, in the U.S.
Dr Reddy’s Laboratories Limited (NSE:DRREDDY) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. InRead More...
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL , 1,000 mg/100 mL , and 1,500 mg/100 mL single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation’s Levetiracetam in Sodium Chloride Injection, approved by the U.S.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District of New Jersey has received and reviewed an emergency application from the plaintiffs in the current patent litigation for a temporary restraining order and preliminary injunction against Dr. Reddy’s. Pending a hearing and decision on the injunction application, the court has issued a temporary restraining order against Dr. Reddy’s with respect to further sales and commercialization of Buprenorphine and Naloxone Sublingual Film within the U.S. The court order does not include a prohibition on commercial manufacturing of the product.
Dr. Reddy’s Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2018 was filed with the United States Securities and Exchange Commission on June 15, 2018.
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
HYDERABAD, India and PRINCETON, N.J. , June 15, 2018 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. ...
India's Dr Reddy's Laboratories (REDY.NS) and U.S.-based Mylan NV (MYL.O) received FDA approval on Thursday for a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue. Generic rivals in tablet form are already on the U.S. market, which is grappling with an opioid addiction epidemic that killed 33,000 people in 2015, but Suboxone Film leads the market with its version which is placed under the tongue to suppress cravings.
Shares in Indivior, which was spun out from Reckitt Benckiser in 2014, were down 22.7 percent at 0925 GMT and the biggest loser on the FTSE midcap index. India's Dr Reddy's Laboratories received FDA approval for a copy-cat version of the treatment, which has been rapidly losing market share due to competition from generics.
Dr. Reddy’s Laboratories Ltd. announced today that it has received final approval from the U.S. Food and Drug Administration and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone® sublingual film, in the United States market.